Gilead Sciences
GILD
$146.85
+1.82%
Gilead Sciences is a research-based biopharmaceutical company that discovers, develops, and commercializes therapies for life-threatening infectious diseases, with its core franchise anchored in HIV treatment and prevention and hepatitis B and C, complemented by a growing oncology portfolio built through the Kite (Yescarta/Tecartus) and Immunomedics (Trodelvy) acquisitions. As one of the largest pure-play antiviral franchises in the industry, Gilead holds a dominant, near-franchise-like position in HIV — where its regimens remain standards of care — while positioning itself as a challenger in cell therapy and antibody-drug conjugates in oncology. The current investor narrative is defined by a tug-of-war between Gilead's reinvigorated HIV growth story — highlighted by the Bixlenvo approval and raised 2026 HIV sales guidance — and an aggressive, debt-funded M&A spree that has included the $7.8 billion Arcellx CAR-T deal, a $3.15 billion Tubulis acquisition, and a $1.5 billion-plus inflammation pipeline purchase. That dealmaking has been punctuated by clinical setbacks, including the termination of the Trodelvy-Keytruda lung cancer trial with Merck, which underscores the binary risk of pipeline expansion. Meanwhile, a Q2 2026 GAAP loss driven by a large one-time acquired in-process R&D charge has muddied headline profitability even as the underlying commercial business continues to compound.…
GILD
Gilead Sciences
$146.85
Related headlines
Investment Opinion: Should I buy GILD Today?
We rate GILD a Buy, based on its compelling valuation, robust cash flow, and reaccelerating HIV business. The analyst consensus is Buy (mean 1.70) with an average target of $158.65, implying 9.6% upside. The core thesis is that Gilead's forward P/E of 14.64x undervalues its stable, high-margin HIV franchise and optionality from oncology pipeline.
Supporting evidence includes: 1) Revenue growth of 10.2% YoY in Q2 2026, driven by HIV; 2) Net margin of 28.9% and operating margin of 39.7%, reflecting strong profitability; 3) TTM free cash flow of $13.2B, which easily covers the 2.62% dividend yield (payout ratio 47%); 4) Forward EPS estimates of $13.09, resulting in a PEG ratio of 0.011, suggesting deep undervaluation relative to growth. Compared to the drug manufacturing industry, Gilead's gross margin of 78.8% is above average, and its EV/EBITDA of 12.5x is reasonable.
Key risks include integration challenges from recent M&A, potential pipeline failures, and HIV concentration. The rating would upgrade to Strong Buy if the stock pulls back to the analyst low target of $123 (15% downside) while fundamentals remain intact, or if oncology pipeline delivers positive late-stage data. It would downgrade to Hold if revenue growth decelerates below 5% or if debt-to-equity exceeds 1.5. At current levels, GILD appears undervalued relative to its cash flow and growth prospects, offering a favorable risk/reward for long-term investors.
Sign up to view all
GILD 12-Month Price Forecast
Gilead presents a compelling risk/reward for long-term investors, with a stable HIV franchise generating strong cash flow and a pipeline that offers optionality. The stock's low beta and dividend yield make it an attractive defensive holding. However, the aggressive M&A strategy introduces binary risk, and recent pipeline setbacks highlight the challenges of diversification. We would upgrade to high confidence if the Arcellx CAR-T program shows positive data or if HIV growth accelerates above 12%. We would downgrade to neutral if debt-to-equity exceeds 1.5 or if free cash flow declines below $10B.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Gilead Sciences's 12-month outlook, with a consensus price target around $159.27 and implied upside of +8.5% versus the current price.
Average Target
$159.27
0 analysts
Implied Upside
+8.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$123 - $180
Analyst target range
Bulls vs Bears: GILD Investment Factors
The bull case currently has stronger evidence, anchored by Gilead's reaccelerating HIV franchise, deep forward earnings multiple, and robust cash flow. The bear case hinges on the binary risk of aggressive M&A and recent pipeline setbacks, but these are long-term concerns that have not yet derailed the core business. The single most important tension is whether the debt-funded oncology and inflammation bets will pay off before the HIV franchise faces generic competition later this decade. If the pipeline delivers, the stock could re-rate toward the analyst high target; if not, the leveraged balance sheet could become a burden.
Bullish
- HIV Franchise Reaccelerates: Q2 2026 revenue grew 10.2% YoY to $7.80B, driven by the Bixlenvo approval and raised 2026 HIV sales guidance. This marks a clear inflection from the prior year's modest growth, with the HIV segment remaining the dominant profit engine.
- Deep Value on Forward Earnings: Forward P/E of 14.64x and PEG ratio of 0.011 (based on trailing growth) suggest the stock trades at a significant discount to the broader market and its own historical multiple. Analyst EPS estimates of $13.09 for the next fiscal year imply a forward earnings yield of 6.8%.
- Robust Cash Generation Supports Dividend: TTM free cash flow stands at $13.2B, comfortably covering the 2.62% dividend yield with a payout ratio of 47%. This provides ample capacity to fund both the dividend and ongoing M&A without straining the balance sheet.
- Analyst Consensus Sees Upside: With 26 analysts covering, the average target price is $158.65, implying 9.6% upside from the current $144.74. The recommendation mean of 1.70 (Buy) reflects strong confidence in the pipeline and commercial execution.
Bearish
- Debt-Funded M&A Raises Integration Risk: The $7.8B Arcellx deal, $3.15B Tubulis acquisition, and $1.5B inflammation purchase have pushed debt-to-equity to 1.10, increasing financial leverage. These bets carry binary clinical risk, as evidenced by the terminated Trodelvy-Keytruda trial.
- GAAP Profitability Distorted by Charges: Q2 2026 GAAP EPS was -$8.45 due to a $12.9B acquired IPR&D charge, resulting in a net loss of $10.5B. While non-GAAP earnings remain positive, the magnitude of these charges highlights the earnings volatility from dealmaking.
- Pipeline Setbacks Threaten Growth: The termination of the Trodelvy-Keytruda lung cancer trial with Merck removes a potential near-term catalyst and underscores the high-risk nature of oncology expansion. This failure could delay the company's diversification away from HIV.
- Relative Performance Lags Recently: Over the past month, GILD underperformed the S&P 500 by 3.85 percentage points, with a -3.26% decline versus SPY's +0.59% gain. This recent weakness may signal waning momentum after a strong 1-year run (+30.9%).
GILD Technical Analysis
Beta
0.33
0.33x market volatility
Max Drawdown
-22.0%
Largest decline past year
52-Week Range
$114-$157
Price range past year
Annual Return
+25.7%
Cumulative gain past year
| Period | GILD Return | S&P 500 |
|---|---|---|
| 1m | -2.7% | +0.9% |
| 3m | +8.9% | +3.4% |
| 6m | +5.7% | +14.4% |
| 1y | +25.7% | +16.2% |
| ytd | +20.8% | +14.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GILD Fundamental Analysis
Quarterly Revenue
$7.8B
2026-06
Revenue YoY Growth
+10.2%
YoY Comparison
Gross Margin
79.8%
Latest Quarter
Free Cash Flow
$13.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GILD Overvalued?
PE
17.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 8x~26x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.5x
Enterprise Value Multiple
Investment Risk Disclosure
Gilead's financial risks are primarily tied to its increased leverage from recent acquisitions. Debt-to-equity stands at 1.10, and the company took on significant debt to fund the $7.8B Arcellx, $3.15B Tubulis, and $1.5B inflammation deals. While TTM free cash flow of $13.2B provides ample coverage, the Q2 2026 GAAP loss of $10.5B (driven by a $12.9B IPR&D charge) illustrates how M&A can create earnings volatility. Additionally, revenue remains concentrated in HIV, which accounted for a majority of sales; any competitive or pricing pressure in that franchise would disproportionately impact results.
Market and competitive risks include valuation compression if growth slows. GILD trades at a forward P/E of 14.64x, which is not demanding, but its price-to-book of 6.73x is elevated relative to peers. The low beta of 0.35 reduces market correlation risk, but sector rotation away from healthcare could still pressure the stock. Recent news highlights pipeline setbacks, such as the terminated Trodelvy-Keytruda trial, which could undermine confidence in the oncology strategy. Furthermore, the threat of drug tariffs (as mentioned in recent news) could disrupt global supply chains and margins, although Gilead may be exempt.
In a worst-case scenario, a major clinical failure in the Arcellx CAR-T program or another late-stage asset, combined with HIV sales deceleration, could trigger a sharp sell-off. The 52-week low is $109.66, representing a 24.2% decline from the current price of $144.74. The analyst low target of $123.00 implies a 15.0% downside. If the bear case materializes, investors could lose 15-24% from current levels, with the stock potentially testing the 52-week low if sentiment deteriorates further.
FAQ
The most severe risk is pipeline failure, particularly in the Arcellx CAR-T program, which could result in a significant write-down and loss of confidence. Financial risk stems from increased leverage, with debt-to-equity at 1.10 and a recent GAAP loss of $10.5B due to IPR&D charges. Competitive risk includes potential market share erosion in HIV from new entrants, though Gilead's regimens remain standard of care. Macro risk is low given the 0.35 beta, but drug pricing legislation or tariffs could impact margins. Additionally, the company's revenue concentration in HIV means any slowdown there would disproportionately affect results.
Our 12-month forecast has a base case (55% probability) targeting $155-165, aligned with the analyst average of $158.65, assuming steady HIV growth and no major pipeline surprises. The bull case (25% probability) targets $170-180 if pipeline successes drive multiple expansion. The bear case (20% probability) targets $110-125 if pipeline failures or HIV deceleration occur. The most likely scenario is the base case, hinging on continued mid-single-digit revenue growth and successful integration of acquisitions. Key assumptions include stable HIV sales, no major trial failures, and manageable debt levels.
GILD trades at a forward P/E of 14.64x, which is below the broader market and its own historical average, suggesting undervaluation. Its price-to-book of 6.73x is high, but that reflects the asset-light nature of pharma and the value of intangible pipeline assets. The EV/EBITDA of 12.52x is reasonable for a large-cap pharma with stable cash flows. Compared to peers, GILD's PEG ratio of 0.011 indicates it is cheap relative to expected growth. The market appears to be pricing in pipeline risks and integration challenges, but not the full potential of the HIV franchise or oncology pipeline. If the company delivers on its guidance, the stock could re-rate higher.
GILD appears attractively valued with a forward P/E of 14.64x and a PEG ratio of 0.011, suggesting it is undervalued relative to its growth. The analyst consensus is Buy with an average target of $158.65, implying 9.6% upside. The company generates $13.2B in TTM free cash flow, supporting a 2.62% dividend yield. However, the stock carries risks from its debt-funded M&A spree, including a debt-to-equity of 1.10 and recent pipeline setbacks. For long-term investors comfortable with binary pipeline risk, GILD offers a favorable risk/reward, especially given its low beta of 0.35. It may not be suitable for those seeking high growth or minimal volatility.
GILD is best suited for long-term investment, given its stable cash flows, dividend yield of 2.62%, and pipeline potential that may take years to materialize. The low beta of 0.35 makes it a defensive holding, but short-term trading is less attractive due to limited volatility and binary event risk. The company's earnings visibility is moderate, with quarterly fluctuations from M&A charges. A minimum holding period of 2-3 years is recommended to allow for pipeline readouts and integration benefits. Short-term traders might find opportunities around earnings or clinical data releases, but the stock is not a high-momentum play.